PURPOSE Our study intended to explore the association between combining 18F-FDG PET/CT metabolic parameters and other clinical features and anaplastic lymphoma kinase (ALK) or c-ros oncogene 1 (ROS1) fusion in non-small-cell lung cancer (NSCLC). METHODS Eight hundred and six patients with wild-type epidermal growth factor receptor (EGFR) mutation were screened for ALK or ROS1 fusion and subjected to 18F-FDG PET/CT prior to treatment at our hospital. The associations between ALK or ROS1 fusion and clinical characteristics and the PET/CT parameters were analyzed. Multivariate logistic regression analysis was performed to explore independent deterministic factors associated with ALK and ROS1 fusion. RESULTS Eighty-two patients (11.7%) with ALK fusion were found. Multivariate analysis demonstrated that high pSUVmax ≥ 10.6, low primary tumor lesion glycolysis (pTLG) < 101.8, young age, nonsmoker status, and high carcinoembryonic antigen (CEA) level correlated with ALK fusion in NSCLC. The receiver operating characteristic (ROC) curve yielded the area under curve (AUC) values of 0.603 and 0.873 for high pSUVmax alone and the combination of the five factors, respectively. Twenty-six patients (5.6%) with ROS1 fusion were found. Multivariate analysis revealed that high pSUVmax ≥ 8.8, young age, and nonsmoker status correlated with ROS1 fusion in NSCLC. The ROC curve yielded AUC values of 0.662 and 0.813 for high pSUVmax alone and the combination of the three factors, respectively. CONCLUSION The study indicated that combining 18F-FDG PET/CT metabolic parameters and other clinical parameters were correlated with ALK and ROS1 mutation in NSCLC patients and may help to refine the process of optimal patient selection to gene test for targeted therapy.

中文翻译：

---

非小细胞肺癌患者结合18F-FDG PET / CT代谢参数和其他临床特征与ALK或ROS1融合之间的相关性。

目的本研究旨在探讨在非小细胞肺癌（NSCLC）中结合18F-FDG PET / CT代谢参数和其他临床特征与间变性淋巴瘤激酶（ALK）或c-ros癌基因1（ROS1）融合之间的关联。方法在我院就诊的806例野生型表皮生长因子受体（EGFR）突变患者中，筛选ALK或ROS1融合蛋白并进行18F-FDG PET / CT检查。分析了ALK或ROS1融合与临床特征和PET / CT参数之间的关联。进行多元逻辑回归分析以探索与ALK和ROS1融合相关的独立确定性因素。结果发现82例ALK融合患者（11.7％）。多因素分析表明，pSUVmax≥10.6，NSCLC中低原发性肿瘤病灶糖酵解（pTLG）<101.8，年轻，不吸烟者状态和高癌胚抗原（CEA）水平与ALK融合相关。接收器工作特性（ROC）曲线分别针对高pSUVmax和五个因素的组合得出的曲线下面积（AUC）值为0.603和0.873。发现26例ROS1融合患者（5.6％）。多因素分析表明，NSCLC中pSUVmax≥8.8，高龄，不吸烟者状态与ROS1融合有关。仅对于高pSUVmax和这三个因素的组合，ROC曲线得出的AUC值分别为0.662和0.813。